Ion Channel Selectivity Profiling Assays

Identification of a compound’s target specificity and potential for off-target effects is a critical step in the drug discovery process and often includes assessments against specific target class families, critical safety targets or by therapeutic area. Charles River offers the largest collection of validated functional assays for ion channel selectivity profiling. Our ion channel portfolio includes over 120 assays, which have been organized into Channel Panels® based on current scientific findings. We can provide functional, manual and automated ion channel screening by therapeutic area for profiling and risk assessment.

Upcoming Webinar

Assessing Neurological Ion Channel Therapeutic and Liability Targets
Thursday, February 16
11:00 a.m.–12:00 p.m.

Register Now »

Available Channel Panels®

You may also be interested in...

Key Ligand-Gated Ion Channels In CNS Drug Discovery

This webinar focuses on studies of neurotransmitter-activated ion channels, as well as GABAA, NMDA and nicotinic acetylcholine receptors, in that they are validated therapeutic targets in neurological disorders.

Comprehensive In Vitro Proarrhythmia Assay (CiPA)

The comprehensive in vitro proarrhythmia assay (CiPA) shifts the emphasis away from QT prolongation and focuses on predicting torsadogenic hazard through an expansion of the in vitro component of nonclinical safety evaluation.